Head-to-head evidence
ICP-332 vs TLL-018
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline
ICP-332
Developed by Beijing InnoCare Pharma Tech Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
TLL-018
Developed by Hangzhou Highlightll Pharmaceutical
NCT05772520 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ICP-332's landscape · TLL-018's landscape